Trial · NCT06016556
A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
NCT06016556, Completed, Pfizer; results first posted 2025-04-29
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia. Trials, record NCT06016556. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06016556
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
- NCT number
- NCT06016556
- Status
- Completed
- Enrollment
- 250 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- Covid-19
- Interventions
- nirmatrelvir, ritonavir
- First posted
- 2023-08-29
- Last updated
- 2025-06-05
- Results first posted
- 2025-04-29
Source ClinicalTrials.gov
Registered outcomes40
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Classified According to Education Level at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Education level classification: no formal education, primary school, secondary school, undergraduate university degree, master's degree and Doctor of Philosophy (PhD) or doctorate. Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Classified According to Employment Status at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Employment status classification: full-time employment, part-time employment, homemaker, retired, student, disabled/too ill to work, and unemployed. Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Height at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Weight at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Body Mass Index (BMI) at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | BMI was calculated based on the reported weight and height in the unit of kilograms over squared meters (kg/m\^2). Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Classified According to Smoking Status at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Smoking status classification: current smoker, former smoker and never smoker. Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Who Had at Least 1 Pre-existing Comorbidity at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants Who Had at Least 1 Concomitant Medication for Comorbidities at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Number of Participants With COVID-19 Infection During the Last 6 Months Prior to Index Date | During 6 months prior to index date, information obtained at index date; retrospective data was evaluated during approximately 6 months of this study | Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
| Primary | Duration Between Last COVID-19 Infection and Index Date | From 6 months prior to index date up to index date, information obtained at index date; retrospective data was evaluated during approximately 6 months of this study | Duration (in months) between COVID-19 infection in last 6 months prior to index date and index date was reported in this outcome measure. Index date was defined as the date of nirmatrelvir, ritonavir (PAXLOVIDTM) treatment prescription, which could be any day between 1-Apr-2022 to 30-Jun-2023 (15-month look back period). |
1 to 10 of 40Source ClinicalTrials.gov
See all 40 registered outcomesOutcomes40
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Classified According to Education Level at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. Here, Overall Number of Participants Analyzed signifies those number of participants who had non-missing values and were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Classified According to Employment Status at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. Here, Overall Number of Participants Analyzed signifies those number of participants who had non-missing values and were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Height at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. Here, ''Overall Number of Participants Analyzed'' signifies number of participants who had non-missing values and were evaluable for this outcome measure. | Meters | MEAN |
| PRIMARY | Weight at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. Here, ''Overall Number of Participants Analyzed'' signifies number of participants who had non-missing values and evaluable for this outcome measure. | Kilograms | MEAN |
| PRIMARY | Body Mass Index (BMI) at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. Here, ''Overall Number of Participants Analyzed'' signifies number of participants who had non-missing values and evaluable for this outcome measure. | Kg/m^2 | MEAN |
| PRIMARY | Number of Participants Classified According to Smoking Status at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. Here, Overall Number of Participants Analyzed signifies those number of participants who had non-missing values and were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Had at Least 1 Pre-existing Comorbidity at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Had at Least 1 Concomitant Medication for Comorbidities at Index Date | At index date; retrospective data was evaluated during approximately 6 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. Here, Overall Number of Participants Analyzed signifies those number of participants who had non-missing values and were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With COVID-19 Infection During the Last 6 Months Prior to Index Date | During 6 months prior to index date, information obtained at index date; retrospective data was evaluated during approximately 6 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. Here, Overall Number of Participants Analyzed signifies those number of participants who had non-missing values and were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Duration Between Last COVID-19 Infection and Index Date | From 6 months prior to index date up to index date, information obtained at index date; retrospective data was evaluated during approximately 6 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. Here, ''Overall Number of Participants Analyzed'' signifies participants evaluable for this outcome measure. | Months | MEAN |
1 to 10 of 40Source ClinicalTrials.gov
See all 40 outcomesResults by group93
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Classified According to Education Level at Index Date | All Participants | No formal education | 32 | Participants | |
| Number of Participants Classified According to Education Level at Index Date | All Participants | Primary school | 1 | Participants | |
| Number of Participants Classified According to Education Level at Index Date | All Participants | Secondary school | 22 | Participants | |
| Number of Participants Classified According to Education Level at Index Date | All Participants | Undergraduate university degree | 85 | Participants | |
| Number of Participants Classified According to Education Level at Index Date | All Participants | Master's degree | 0 | Participants | |
| Number of Participants Classified According to Education Level at Index Date | All Participants | PhD or doctorate | 0 | Participants | |
| Number of Participants Classified According to Employment Status at Index Date | All Participants | Full-time employment | 41 | Participants | |
| Number of Participants Classified According to Employment Status at Index Date | All Participants | Part-time employment | 1 | Participants | |
| Number of Participants Classified According to Employment Status at Index Date | All Participants | Homemaker | 10 | Participants | |
| Number of Participants Classified According to Employment Status at Index Date | All Participants | Retired | 42 | Participants |
1 to 10 of 93Source ClinicalTrials.gov
See all 93 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | All Participants | 248 | |
| Overall Study | COMPLETED | All Participants | 248 | |
| Overall Study | NOT COMPLETED | All Participants | 0 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Drug-Drug Interaction | General disorders | All Participants | 2 | 248 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | All Participants | 0 | 248 |
| Total, other adverse events | All Participants | 0 | 248 |
| Total, serious adverse events | All Participants | 2 | 248 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42156669 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06016556
GET https://conductscience.org/api/trials/v1/NCT06016556/registered?page=2